drugset / Trial / NCT01845077
Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of the trial is to demonstrate the relative bioavailability of 2 newly developed fixed dose combination (FDC) tablets containing linagliptin \& metformin and the single tablets of linagliptin and metformin when administered singularly.
Timeline
- Start
- 2013-05
- Primary completion
- 2013-08
- Completion
- 2013-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Linagliptin | Small molecule | 5 mg | — |
| Subject | Linagliptin/Metformin | Unknown | 1000 mg | — |
| Subject | Linagliptin/Metformin | Unknown | 1500 mg | — |
| Comparator | Metformin | Small molecule | 1000 mg | — |
| Comparator | Metformin | Small molecule | 1500 mg | — |
Indications
No indication recorded.